Intraoperative pyloric botulinum toxin injection during Ivor–Lewis gastroesophagectomy to prevent delayed gastric emptying. Issue 6 (17th December 2018)

• Record Type: Journal Article
• Authors: Tham, J C; Nixon, M; Ariyarathenam, A V; Humphreys, L; Berrisford, R; Wheatley, T; Sanders, G
• Is Part Of: Diseases of the esophagus. Volume 32:Issue 6(2019)
• Publication Date: 2018-12-17
• Subjects: gastric emptying -- Ivor Lewis -- esophageal cancer -- esophageal and gastric surgery; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1093/dote/doy112
• Languages: English
• ISSNs: 1120-8694

Abstract

SUMMARY: Delayed gastric emptying (DGE) is a common morbidity that affects 10%–50% of Ivor–Lewis gastroesophagectomy (ILGO) patients. DGE management is variable with no gold standard prevention or treatment. We conducted a study to assess the effectiveness of intraoperative pyloric botulinum toxin injection in preventing DGE. All patients undergoing an ILGO for curative intent, semi-mechanical anastomosis, and enhanced recovery between 1st December 2011 and 30th June 2017 were included. Patients with pyloroplasties were excluded and botulinum toxin was routinely given from the 2nd April 2016. We compared botulinum toxin injection (BOTOX) against no intervention (NONE) for patient demographics, adjuvant therapy, surgical approach, DGE incidence, length of stay (LOS), and complications. Additionally, we compared pneumonia risk, anastomotic leak rate, and LOS in DGE versus non-DGE patients. DGE was defined using nasogastric tube input/output differences and chest X-ray appearance according to an algorithm adopted in our unit, which were retrospectively applied. There were 228 patients: 65 (28.5%) received botulinum toxin and 163 (71.5%) received no intervention. One hundred twenty-four (54.4%) operations were performed laparoscopically, of which 11 (4.8%) were converted to open procedures, and 104 (45.6%) were open operations. DGE incidence was 11 (16.9%) in BOTOX and 29 (17.8%) in NONE, P = 0.13. Medical management was required in 14 of 228 (6.1%) cases: 3 (4.6%) in BOTOX and 11 (4.8%) in NONE. Pyloric dilatation was required in 26 of 228 (11.4%): 8 of 65 (12.3%) in the BOTOX and 18 of 163 (11.0%) in NONE. There were no significant differences between groups and requirement for intervention, P = 0.881. Overall median LOS was 10 (6.0–75.0) days: 9 (7.0–75.0) in BOTOX and 10 (6.0–70.0) in NONE, P = 0.516. In non-DGE versus DGE patients, median LOS was 9 (6–57) versus 14 (7–75) days ( P < 0.0001), pneumonia incidence of 27.7% versus 30.0% ( P = 0.478), and anastomotic leak rate of 2.1% versus 10.0% ( P = 0.014). Overall leak rate was 3.5%. Overall complication rate was 67.1%, including minor/mild complications. There were 43 of 65 (66.2%) in BOTOX and 110 of 163 (67.5%) in NONE, P = 0.482. In-hospital mortality was 1 (0.44%), 30-day mortality was 2 (0.88%), 90-day mortality was 5 (2.2%), and there were no 30-day readmissions. Intraoperative pyloric botulinum toxin injections were ineffective in preventing DGE (BOTOX vs. NONE: 16.9% vs. 17.8%) or reducing postoperative complications. DGE was relatively common (17.5%) with 11.4% of patients requiring postoperative balloon dilatation. DGE also resulted in prolonged LOS (increase from 9 to 14 days) and significant increase in leak rate from 2.1% to 10.0%. A better understanding of DGE will guide assessment, investigation, and management of the condition.